Savara Inc's business model revolves around developing and commercializing novel therapies for the treatment of rare respiratory diseases. The company focuses on developing inhalation therapies that address significant unmet needs in conditions like pulmonary disease, cystic fibrosis, and asthma. Savara Inc adopts a patient-centric approach, aiming to improve the lives of individuals with these conditions through innovative and effective treatments. By conducting clinical trials, engaging in strategic collaborations, and leveraging its expertise in pulmonary delivery, the company strives to bring transformative therapies to market and positively impact the healthcare landscape for respiratory diseases.

Savara Inc primarily operates in the pharmaceutical and biotechnology industries. This Texas-based company focuses on developing and commercializing innovative therapies for the treatment of rare respiratory diseases. With a strong commitment to pioneering research and development, Savara Inc aims to provide advanced medical solutions to patients globally.

The main competitors of Savara Inc in the market include companies such as Insmed Incorporated, PTC Therapeutics, Inc., and Verona Pharma plc.

Savara Inc is a pharmaceutical company specializing in rare respiratory diseases. Founded in 2007, Savara is dedicated to developing novel treatments for patients with pulmonary disorders, including cystic fibrosis (CF) and non-tuberculous mycobacterial (NTM) lung infections. The company's mission revolves around improving the lives of those affected by these conditions, leveraging its expertise in research, clinical development, and commercialization. Savara's commitment to innovation and collaboration has enabled the advancement of potential breakthrough therapies, such as its lead investigational drug candidate, Molgradex, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). Through strategic partnerships and a patient-centric approach, Savara Inc continues to drive advancements in respiratory care.

Savara Inc, a leading pharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed a Phase 3 clinical trial for its innovative treatment targeting rare pulmonary diseases. Additionally, Savara Inc received FDA Fast Track designation and Orphan Drug designations for its key products, highlighting the potential benefits they offer to patients. The company also formed strategic partnerships with reputable organizations, expanding its research and development capabilities. Moreover, Savara Inc's stock witnessed notable growth and recognition within the market, signifying investors' confidence in the company's future prospects. These remarkable milestones demonstrate Savara Inc's commitment to advancing medical solutions for respiratory disorders, solidifying its position in the healthcare industry.

Savara Inc primarily operates in the United States, with its headquarters located in Austin, Texas.

Savara Inc represents a set of values and corporate philosophy focused on innovation, patient-centricity, and dedication to improving the lives of those affected by serious respiratory conditions. The company's commitment to cutting-edge research and development enables them to deliver advanced treatment options and solutions to patients in need. With a strong emphasis on scientific excellence and collaboration, Savara Inc strives to create a positive impact in the healthcare industry. By continually pushing the boundaries of respiratory care, Savara Inc aims to improve patient outcomes and drive meaningful change in the field.

Analysts currently set an average price target of 11,03 USD for the Savara stock (median: 10,46 USD), implying +101,8 % versus the latest price. The consensus is based on 14 analyst ratings.

Savara Analyytikkojen kursstavoitteet 2026

14 analysts currently rate the Savara stock: 13 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Savara to generate revenue of 3,18 M USD and earnings per share of −0,48 USD.

Savara Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Savara share trades at 4,80 EUR (5,47 USD).

The Savara share (SVRA) is listed on 4 stock exchanges, including: NASDAQ (SVRA), Frankfurt (YB4P.F), München (YB4P.MU), Düsseldorf (YB4P.DU).

Savara Inc is a biopharmaceutical company specializing in the development and marketing of therapeutics for rare respiratory diseases. The company aims to help patients with rare lung diseases and improve their quality of life. Savara's business model is based on research, development, and marketing of innovative solutions for severe and life-threatening diseases. Savara currently offers a wide range of therapeutics for patients with cystic fibrosis and other rare lung diseases. The company has developed unique technologies and a deep understanding of respiratory diseases. Savara strives to develop medications for patients who do not have adequate treatment options. The company is divided into three divisions: Research and development, clinical trials, and marketing. The research and development division is responsible for identifying new molecules and technologies for the treatment of lung diseases. Savara has a team of scientists and clinical trial experts working on the development of medications for lung diseases. Savara's clinical trials division aims to improve the effectiveness and safety of therapeutics through high-quality clinical trials. By conducting studies in collaboration with doctors and clinicians, Savara ensures that the data provide the necessary information to improve patient treatment. Savara's marketing division is responsible for the introduction and marketing of the company's products. Savara works closely with leading medical experts to make the benefits of therapeutics accessible to affected patients and healthcare professionals. The company aims to establish a long-term relationship with patients, offering valuable information and support. Savara's main products currently include AIR001 and Molgradex, which are used for the treatment of lung diseases such as pulmonary hypertension and the autoimmune disease granulomatosis with polyangiitis. AIR001 is a gas phase nitric oxide (NO) donor that aims to improve blood flow in the lungs. On the other hand, Molgradex is a recombinant human granulocyte-macrophage colony-stimulating factor used in the treatment of pulmonary alveolar proteinosis (PAP). Overall, Savara's business model is characterized by its focus on the development and marketing of therapeutics exclusively for rare lung diseases. Savara aims to address unmet medical needs through continuous research and close collaboration with healthcare professionals and patients. Answer: Savara Inc is a biopharmaceutical company specializing in the development and marketing of therapeutics for rare respiratory diseases.

odotettu liikevaihto Savara on 3,18 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Savara on −105,93 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Savara:n hinta-voitto-suhde (P/E) on tällä hetkellä −11,47. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Savara-osakkeen arvostusta.

Savara:n hinta-myynti-suhde (P/S) on tällä hetkellä 382,32. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Savara-osakkeen arvostuskennuslukuna.

Savara:n Eulpool-laatuscore on 2/10.

Savara:n ISIN on US8051111016. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Savara:n WKN on A2DQ2B. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Savara:n ticker on SVRA. Tämä pörssinoteeraus käytetään Savara-osakkeiden kauppaan pörssissä.

Savara maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Savara kuuluu sektoriin 'Terveydenhuolto'.

Savara:n osingot jaetaan valuutassa USD.